{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T21:42:49Z","timestamp":1773265369794,"version":"3.50.1"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>The clinical manifestations of lung cancer are diverse. Presentation initially as the Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) is relatively uncommon. This article reports the diagnosis and treatment process of a 76-year-old male patient with hyponatremia, ultimately diagnosed with SIADH attributed to small cell lung cancer (SCLC). The patient presented with fatigue and significant hyponatremia. Comprehensive investigation excluded adrenal, thyroid, and other functional abnormalities. Combined with features including high urinary sodium, euvolemic status, and normal renal function, the findings were consistent with a diagnosis of SIADH. Subsequent imaging and pathological examinations revealed the etiology to be SCLC. Management included fluid restriction, sodium supplementation, and the use of tolvaptan. Subsequent chemotherapy and radiotherapy for the SCLC led to the gradual normalization of serum sodium. This article reviews the literature in conjunction with this case, summarizing the diagnostic approach to hyponatremia, as well as the diagnostic workup, pathophysiological mechanisms, and treatment strategies for SIADH, aiming to enhance the early recognition and comprehensive management of this condition.<\/jats:p>","DOI":"10.3389\/fendo.2026.1780594","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T05:37:15Z","timestamp":1773207435000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Refractory hyponatremia in small cell lung cancer: a case report and literature review"],"prefix":"10.3389","volume":"17","author":[{"given":"Suqing","family":"Bao","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Tianjin First Central Hospital","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Qin","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Tianjin First Central Hospital","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Tianjin First Central Hospital","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Tianjin First Central Hospital","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijun","family":"Duan","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Tianjin First Central Hospital","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.0000000588","article-title":"Syndrome of inappropriate antidiuresis","volume":"36","author":"Rosner","year":"2025","journal-title":"J Am Soc Nephrol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-13-1020","article-title":"Hyponatraemia Guideline Development Group. Clinical practice guideline on diagnosis and treatment of hyponatraemia","volume":"170","author":"Spasovski","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2022050623","article-title":"Treatment effect of the SGLT2 inhibitor empagliflozin on chronic syndrome of inappropriate antidiuresis: results of a randomized, double-blind, placebo-controlled, crossover trial","volume":"34","author":"Refardt","year":"2023","journal-title":"J Am Soc Nephrol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"102055","DOI":"10.1016\/j.beem.2025.102055","article-title":"New potential treatment options for syndrome of inappropriate antidiuresis","volume":"40","author":"Monnerat","year":"2025","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.11176","article-title":"Diagnosis and management of hyponatremia: A review","volume":"328","author":"Adrogu\u00e9","year":"2022","journal-title":"JAMA"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.2147\/CIA.S138535","article-title":"Hyponatremia in the elderly: challenges and solutions","volume":"12","author":"Filippatos","year":"2017","journal-title":"Clin Interv Aging"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnad010","article-title":"Syndrome of inappropriate antidiuresis: from pathophysiology to management","volume":"44","author":"Warren","year":"2023","journal-title":"Endocr Rev"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfae162","article-title":"Hyponatraemia-treatment standard 2024","volume":"39","author":"Spasovski","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp2210411","article-title":"The syndrome of inappropriate antidiuresis","volume":"389","author":"Adrogu\u00e9","year":"2023","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"102066","DOI":"10.1016\/j.beem.2025.102066","article-title":"Hyponatraemia and cancer","volume":"40","author":"Naldi","year":"2025","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2022.02.015","article-title":"Syndrome of inappropriate antidiuretic hormone secretion","volume":"159","author":"Poch","year":"2022","journal-title":"Med Clin (Barc)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac245","article-title":"Approach to the patient: hyponatremia and the syndrome of inappropriate antidiuresis (SIAD)","volume":"107","author":"Martin-Grace","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B13","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/cncr.23542","article-title":"Bronchopulmonary neuroendocrine tumors","volume":"113","author":"Gustafsson","year":"2008","journal-title":"Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.0560","article-title":"Small cell lung cancer: A review","volume":"333","author":"Kim","year":"2025","journal-title":"JAMA"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1382066","article-title":"Case report: Secondary failure to tolvaptan in a patient with SCLC and paraneoplastic SIADH","volume":"15","author":"Menzi","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-24-0265","article-title":"Small cell lung cancer neuronal features and their implications for tumor progression, metastasis, and therapy","volume":"22","author":"Hartmann","year":"2024","journal-title":"Mol Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/ejendo\/lvaf115","article-title":"Severe symptomatic hyponatremia in Europe: insights into current clinical practice","volume":"192","author":"Beck","year":"2025","journal-title":"Eur J Endocrinol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2025.04.012","article-title":"Low-dose tolvaptan for the treatment of syndrome of inappropriate antidiuretic hormone-associated hyponatremia: A systematic review, meta-analysis, and meta-regression analysis of clinical effectiveness and safety","volume":"31","author":"Lewellyn","year":"2025","journal-title":"Endocr Pract"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12175483","article-title":"Safety and efficacy of vaptans in the treatment of hyponatremia from syndrome of inappropriate antidiuretic hormone secretion (SIADH): A systematic review and meta-analysis","volume":"12","author":"Krisanapan","year":"2023","journal-title":"J Clin Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1159\/000509082","article-title":"SGLT-2 inhibitors to treat hyponatremia associated with SIADH: A novel indication","volume":"51","author":"Sarafidis","year":"2020","journal-title":"Am J Nephrol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2019090944","article-title":"A randomized trial of empagliflozin to increase plasma sodium levels in patients with the syndrome of inappropriate antidiuresis","volume":"31","author":"Refardt","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-022-00673-x","article-title":"Efficacy of empagliflozin for syndrome of inappropriate antidiuresis","volume":"19","author":"Carney","year":"2023","journal-title":"Nat Rev Nephrol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1780594\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T05:37:15Z","timestamp":1773207435000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1780594\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":22,"alternative-id":["10.3389\/fendo.2026.1780594"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1780594","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,11]]},"article-number":"1780594"}}